title: Hedgehog pathway activity in pediatric embryonal rhabdomyosarcoma and undifferentiated sarcoma: a report from the Children's Oncology Group.
abstract: BACKGROUND
  Aberrant activation of the hedgehog (Hh) signaling pathway is implicated widely in both pediatric and adult malignancies. Inactivation of the Hh regulator PTCH is responsible for the Gorlin cancer predisposition syndrome. The spectrum of tumors found in Gorlin Syndrome includes basal cell carcinoma, medulloblastoma, and rarely, rhabdomyosarcoma (RMS). A previous report utilizing in situ hybridization has provided initial evidence for the expression of Hh targets GLI1 and PTCH in RMS tumors.
  
  
  METHODS
  To investigate the role of Hh pathway signaling in pediatric RMS and undifferentiated sarcoma (US) tumors, the expression of Hh pathway targets GLI1 and PTCH was measured. RNA was extracted from archival human tumor specimens collected from pediatric patients enrolled on Intergroup Rhabdomyosarcoma Study III and IV, and subjected to quantitative reverse transcriptase-polymerase chain reaction.
  
  
  RESULTS
  Expression of GLI1 with or without PTCH was detected in substantial subsets of embryonal RMS (ERMS) and US tumors but only rarely in alveolar RMS tumors. Neither PTCH mutations nor activating SMO mutations were detected in ERMS tumors with high GLI1 expression. Microarray analysis demonstrated relative overexpression of downstream Hh targets in ERMS tumors with high or intermediate GLI1 expression. Unlike a recent report, Hh pathway activity in ERMS tumors did not correlate with a unique clinical phenotype.
  
  
  CONCLUSIONS
  Our findings support a role for Hh pathway activation in the genesis of a subset of ERMS and US tumors. Hh signaling may represent a novel therapeutic target in affected tumors.
authors: Division of Oncology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA. jpressey@uab.edu
authors: Joseph G
authors: JG
authors: Pressey
authors: James R
authors: JR
authors: Anderson
authors: David K
authors: DK
authors: Crossman
authors: James C
authors: JC
authors: Lynch
authors: Frederic G
authors: FG
authors: Barr
references: Science. 2009 Oct 23;326(5952):572-4
references: 19726788
references: Med Pediatr Oncol. 1997 Sep;29(3):170-80
references: 9212841
references: Genes Chromosomes Cancer. 2002 Mar;33(3):310-21
references: 11807989
references: J Clin Oncol. 2001 Jun 15;19(12):3091-102
references: 11408506
references: Oncogene. 2008 May 22;27(23):3282-91
references: 18084326
references: Cancer Chemother Rep. 1966 Mar;50(3):163-70
references: 5910392
references: Cancer Res. 2009 Aug 1;69(15):6007-10
references: 19638582
references: Med Pediatr Oncol. 1983;11(3):178-9
references: 6855699
references: Proc Assoc Am Physicians. 1995 Jul;107(2):253-7
references: 8624861
references: N Engl J Med. 2009 Sep 17;361(12):1173-8
references: 19726761
references: Proc Natl Acad Sci U S A. 2007 May 15;104(20):8455-60
references: 17494766
references: Nature. 2003 Oct 23;425(6960):846-51
references: 14520411
references: Recent Results Cancer Res. 2010;184:235-8
references: 20072843
references: Nature. 2002 Jan 24;415(6870):436-42
references: 11807556
references: Oncogene. 1999 Jan 21;18(3):833-6
references: 9989836
references: EMBO J. 2010 Aug 4;29(15):2646-58
references: 20581804
references: Medicine (Baltimore). 1987 Mar;66(2):98-113
references: 3547011
references: J Pathol. 2006 Jan;208(1):17-25
references: 16294371
references: Genes Chromosomes Cancer. 2000 Apr;27(4):337-44
references: 10719362
references: Mol Cell Biol. 1991 Mar;11(3):1724-8
references: 1825351
references: N Engl J Med. 2009 Sep 17;361(12):1164-72
references: 19726763
references: Genes Dev. 2001 Dec 1;15(23):3059-87
references: 11731473
references: Nat Med. 1998 May;4(5):619-22
references: 9585239
references: Oncogene. 2010 Dec 2;29(48):6323-30
references: 20818440
references: Nat Genet. 2002 Jul;31(3):306-10
references: 12068298
references: J Biol Chem. 2002 Feb 15;277(7):5548-55
references: 11719506